205 related articles for article (PubMed ID: 12019088)
81. Value of the dorsal cutaneous guinea pig model in selecting topical antiviral formulations for the treatment of recurrent herpes simplex type 1 disease.
Poli G; Dall'Ara P; Binda S; Santus G; Poli A; Cocilovo A; Ponti W
Arzneimittelforschung; 2001; 51(5):433-8. PubMed ID: 11413746
[TBL] [Abstract][Full Text] [Related]
82. Helicase-primase inhibitor pritelivir for HSV-2 infection.
Wald A; Corey L; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Kriesel J; Fife K; Galitz L; Stoelben S; Huang ML; Selke S; Stobernack HP; Ruebsamen-Schaeff H; Birkmann A
N Engl J Med; 2014 Jan; 370(3):201-10. PubMed ID: 24428466
[TBL] [Abstract][Full Text] [Related]
83. Antiviral Effects of ABMA against Herpes Simplex Virus Type 2 In Vitro and In Vivo.
Dai W; Wu Y; Bi J; Wang S; Li F; Kong W; Barbier J; Cintrat JC; Gao F; Gillet D; Su W; Jiang C
Viruses; 2018 Mar; 10(3):. PubMed ID: 29522484
[TBL] [Abstract][Full Text] [Related]
84. UL23, UL30, and UL5 characterization of HSV1 clinical strains isolated from hematology department patients.
Labrunie T; Ducastelle S; Domenech C; Ader F; Morfin F; Frobert E
Antiviral Res; 2019 Aug; 168():114-120. PubMed ID: 31152759
[TBL] [Abstract][Full Text] [Related]
85. Roles of the Phosphorylation of Herpes Simplex Virus 1 UL51 at a Specific Site in Viral Replication and Pathogenicity.
Kato A; Oda S; Watanabe M; Oyama M; Kozuka-Hata H; Koyanagi N; Maruzuru Y; Arii J; Kawaguchi Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976672
[TBL] [Abstract][Full Text] [Related]
86. In vitro and in vivo antiherpetic effects of (1R,2R)-1-(5'-methylful-3'-yl)propane-1,2,3-triol.
Sasaki K; Hayashi K; Matsuya Y; Sugimoto K; Lee JB; Kurosaki F; Hayashi T
J Nat Med; 2016 Apr; 70(2):217-24. PubMed ID: 26763002
[TBL] [Abstract][Full Text] [Related]
87. A new promising candidate to overcome drug resistant herpes simplex virus infections.
Zinser E; Krawczyk A; Mühl-Zürbes P; Aufderhorst U; Draßner C; Stich L; Zaja M; Strobl S; Steinkasserer A; Heilingloh CS
Antiviral Res; 2018 Jan; 149():202-210. PubMed ID: 29155164
[TBL] [Abstract][Full Text] [Related]
88. Understanding helicases as a means of virus control.
Frick DN; Lam AM
Curr Pharm Des; 2006; 12(11):1315-38. PubMed ID: 16611118
[TBL] [Abstract][Full Text] [Related]
89. The ribonucleotide reductase inhibitor (E)-2'-fluoromethylene-2'-deoxycytidine (MDL 101,731): a potential topical therapy for herpes simplex virus infection.
Bridges CG; Ahmed SP; Sunkara PS; McCarthy JR; Tyms AS
Antiviral Res; 1995 Aug; 27(4):325-34. PubMed ID: 8540753
[TBL] [Abstract][Full Text] [Related]
90. Efficacy of phosphonoacetic acid on herpes simplex virus infection of sensory ganglia.
Wohlenberg CR; Walz MA; Notkins AL
Infect Immun; 1976 May; 13(5):1519-21. PubMed ID: 178609
[TBL] [Abstract][Full Text] [Related]
91. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
Lebel A; Boivin G
J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
[TBL] [Abstract][Full Text] [Related]
92. The six conserved helicase motifs of the UL5 gene product, a component of the herpes simplex virus type 1 helicase-primase, are essential for its function.
Zhu LA; Weller SK
J Virol; 1992 Jan; 66(1):469-79. PubMed ID: 1309257
[TBL] [Abstract][Full Text] [Related]
93. The effect of oral treatment with 6-O-butanoyl castanospermine (MDL 28,574) in the murine zosteriform model of HSV-1 infection.
Bridges CG; Ahmed SP; Kang MS; Nash RJ; Porter EA; Tyms AS
Glycobiology; 1995 Mar; 5(2):249-53. PubMed ID: 7780200
[TBL] [Abstract][Full Text] [Related]
94. Disease and latency characteristics of clinical herpes virus isolated after acyclovir therapy.
Sibrack CD; McLaren C; Barry DW
Am J Med; 1982 Jul; 73(1A):372-5. PubMed ID: 6285725
[TBL] [Abstract][Full Text] [Related]
95. [Herpes simplex virus resistance to antivirals].
Burrel S; Topalis D; Boutolleau D
Virologie (Montrouge); 2020 Oct; 24(5):325-342. PubMed ID: 33111706
[TBL] [Abstract][Full Text] [Related]
96. Efficacy of orally administered Lobelia chinensis extracts on herpes simplex virus type 1 infection in BALB/c mice.
Kuo YC; Lee YC; Leu YL; Tsai WJ; Chang SC
Antiviral Res; 2008 Nov; 80(2):206-12. PubMed ID: 18621082
[TBL] [Abstract][Full Text] [Related]
97. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
Spector T; Lobe DC; Ellis MN; Blumenkopf TA; Szczech GM
Antimicrob Agents Chemother; 1992 May; 36(5):934-7. PubMed ID: 1324641
[TBL] [Abstract][Full Text] [Related]
98. Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection.
Safrin S; Schacker T; Delehanty J; Hill E; Corey L
J Med Virol; 1993; Suppl 1():146-9. PubMed ID: 8245882
[TBL] [Abstract][Full Text] [Related]
99. Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways.
Sanchez MD; Ochoa AC; Foster TP
Antiviral Res; 2016 Aug; 132():13-25. PubMed ID: 27192555
[TBL] [Abstract][Full Text] [Related]
100. Drug targets in herpes simplex and Epstein Barr Virus infections.
Billaud G; Thouvenot D; Morfin F
Infect Disord Drug Targets; 2009 Apr; 9(2):117-25. PubMed ID: 19275700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
